Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study

YI-CHENG CHANGLEE-MING CHUANGJOU-WEI LINChen, S-TS-TChenLai, M-SM-SLaiCHIA-HSUIN CHANG2023-04-212023-04-212015-110742-3071https://scholars.lib.ntu.edu.tw/handle/123456789/630404To compare the cardiovascular risks associated with second-line oral antidiabetic agents added to initial metformin therapy in a large nationwide observational study.enCORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; GLUCOSE-CONCENTRATION; HYPOGLYCEMIC AGENTS; PIOGLITAZONE; METAANALYSIS; MORTALITY; REPAGLINIDE; MELLITUS; OUTCOMES[SDGs]SDG3Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort studyjournal article10.1111/dme.12800259708142-s2.0-84945456985WOS:000363263800009https://api.elsevier.com/content/abstract/scopus_id/84945456985